[Clinical difference between thiazolidinediones and biguanides].
Hyperglycemia in patients with type 2 diabetes mellitus is caused by peripheral insulin resistance, which results in decreased insulin-mediated glucose disposal and increased endogenous glucose production, and inadequate insulin secretion. Recently, either biguanides or thiazolidinediones among oral hypoglycemic agents is widely used to patients with type 2 diabetes mellitus for reversal of insulin resistance. As clinical difference between biguanides and thiazolidinediones in reducing blood glucose, the former primarily lowers endogenous glucose production presumably at the level of liver, whereas the latter increases insulin-mediated peripheral glucose disposal, which occurs predominantly in skeletal muscle. Therefore, combination therapy with these two drugs results in further improvement in glucose control. Combination therapy including these two drugs is attractive prospects in future treatment for patients with type 2 diabetes.